The ability to use haploidentical donors, or half matched donors, is the most important recent development in stem cell transplantation, says world leader in transplant research, Professor David Curtis.
We spoke to Dr Sidiqi about his specialising field of amyloidosis.
Professor Wendy Erber and her research team in Western Australia are developing a monitoring tool they hope will identify MPN patients who will go on to develop leukaemia.
The greatest unmet need in CML is the ability to predict outcomes at the time of diagnosis according to Dr Naranie Shanmuganathan, a consultant haematologist at Royal Adelaide Hospital and SA Pathology.
Dr Cameron Curley describes CAR T-cell therapy as “arguably the biggest breakthrough in the treatment of many blood cancers in the last decade”.
Find out why the clinical haematologist is dedicating his life to CLL.
It’s emerging in all cancers, but particularly in the MPNs, that “genomics is everything” according to Professor Andrew Perkins, an expert in myeloproliferative neoplasms (MPN).
Noemi Horvath is a highly reputed consultant haematologist at Royal Adelaide Hospital who has dedicated most of her life to her work and her special interest has long been amyloidosis.
Dr Pagani has a vision for a personalised approach to treatment-free remission in CML
